Following the demonstration that adjuvant therapy, especially CMF and tamoxifen, in patients<50 and .50 years respectively, significantly improves survival (Bonadonna et al., 1976; Palshof et al., 1980; NATO, 1983; Ludwig, 1984; Bianco et al., 1988) , efforts have been aimed at identifying patient subgroups that would benefit from the two treatments and strategies that would improve the results of treatments. A number of prospective randomised trials were designed to address specific clinical questions, e.g. optimal timing and scheduling of cytotoxic drugs and hormones; optimal duration of tamoxifen administration; and new strategies of drug administration to overcome tumour resistance.
One of the proposed models involves alternating two noncross-resistant and equally effective drug combinations, according to the Goldie-Coldman hypothesis (Goldie et al., 1982) . These investigators postulated that stable genetic alterations arise in tumour cells and lead to the development of cell phenotypes characterised by drug resistance. Thus, they suggested that the early and concurrent administration of all available anti-tumour agents would be the most effective strategy. However, the overlapping toxic effects of this approach may preclude its clinical application. The next best alternative would be the use of non-cross resistant regimens which, by attacking a population of tumour cells resistant to one therapy but presumably not to the other therapy, would lead to maximal anti-tumour effect and possibly cure more patients.
At the time our study was designed, the evidence of equiactivity and non-cross-resistance of CMF (cyclophosphamide, methotrexate, 5-fluorouracil) and AV (doxorubicin, vincristine) regimens, in addition to promising results in metastatic breast cancer (De Lena et al., 1975; Tormey et al., 1982) , provided the rationale to test the concept of the fixed rotation of the two regimens in an adjuvant setting. Furthermore, the observation that 4-epi-doxorubicin, when used alone or in combination with other cytotoxic agents, resulted in equivalent objective response rates and overall median survival in advanced breast cancer as doxorubicin parental compound-containing regimens, but with lower cardiotoxic potential (Jain et al., 1985) , prompted us to replace AV with EV (4-epi-doxorubicin, vincristine Primary treatment was either radical or modified radical mastectomy or quadrantectomy for tumours < 2 cm followed by high-voltage radiotherapy of the residual breast. Complete axillary node dissection was required in all patients.
Patients were considered post-menopausal if they had had their last menses at least 6 months before randomisation. Oestrogen receptor assay was requested in post-menopausal patients and performed by the biochemical assay described elsewhere (De Placido et al., 1990) .
Patients gave their informed consent to the study. From 31 January 1985 to 31 December 1990, 220 patients entered the trial; 115 were assigned to standard CMF and 105 to alternating CMF/EV. The two arms were similar in the distribution of major prognostic factor (Table I) , although a higher proportion of small tumours ( 2 cm) was observed in the CMF/EV arm.
Drug regimens
The standard CMF regimen was cyclophosphamide l00mgm-2 orally on days 1-14, methotrexate 40mgm-2 and 5-fluorouracil 600 mg m-2 intravenously on days 1 and 8 of a 28 day cycle that was repeated six times. The alternating regimen consisted of the standard 28 day CMF cycle (same dosage as the control arm) in cycles 1, 3 and 5 and a 21 day EV course of 4-epi-doxorubicin 75 mg m-2 on day 1 and vincristin 1.4mgm 2 on days 1 and 8 intravenously in the even cycles, 2, 4 and 6; overall, six cycles were given, as in the control arm.
Treatment toxicity was evaluated in accordance with WHO criteria (Miller et al., 1981) . Amenorrhoea was defined as previously reported (Bianco et al., 1991) .
In both arms chemotherapy was recycled at the planned time if leucocyte and platelet counts were at least 4000 and (Figure 1 ) and OAS (Figure 2) 
Side-effects
Patients generally experienced mild toxicity, which is reported in Table IV . A higher incidence of vomiting and hair loss was observed in the CMFiEV group, while permanent amenorrhoea, diarrhoea, stomachache and minor infections were more frequent in CMF-treated patients. Peripheral neurotoxicity, i.e. constipation or paresthesies, occurred exclusively in the CMF/EV arm, as expected from vincristine toxicity.
Drug compliance
In patients who received CMF, the mean relative dose intensity (RDI) for cyclophosphamide was 0.80, for methotrexate 0.81 and for 5-fluorouracil 0.83. with a mean value for the combination of 0.81. In the alternating therapy arm, the mean RDI for the individual drugs were 0.84 for cyclophosphamide, 0.89 for methotrexate, 0.89 for 5-fluorouracil, 0.79 for 4-epi-doxorubicin and 0.68 for vincristine, and the mean RDI for the treatment regimen was 0.82. Figure 3 shows the RDI for the two combination regimens and for the single drugs in the two arms. Figre I Disease-free survival curves. (De Lena et al., 1975; Tormey et al., 1982 (Kennealeyet al., 1978; Nemotoet al., 1982; Vogel et al., 1984) 
